Literature DB >> 23665030

The immunomodulatory effects of statins in community-acquired pneumonia: a systematic review.

D P R Troeman1, D F Postma, C H van Werkhoven, J J Oosterheert.   

Abstract

OBJECTIVE: To evaluate the potential immunomodulatory effects of statins in community-acquired pneumonia.
METHODS: We performed a systematic review of available literature on experimental and clinical studies. We used a PubMed/MEDLINE and EMBASE search to identify potential articles.
RESULTS: We identified 34 original studies, 17 experimental and 17 clinical studies, published up to March 2013.
CONCLUSIONS: Statins attenuated pulmonary inflammation by modulating neutrophil function, by reducing cytokine expression and release, and by protecting against disruption of pulmonary integrity. However, additional experimental studies are needed to fully elucidate the exact mechanisms. Several clinical studies suggested a decreased risk of CAP or a reduction in mortality due to CAP for current statin users, but the mostly observational design of these studies hampers the interpretation of their results. Therefore, appropriately designed studies, such as randomised controlled trials, are required to demonstrate the usefulness of statins in the prevention and treatment of CAP.
Copyright © 2013 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23665030     DOI: 10.1016/j.jinf.2013.04.015

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  11 in total

Review 1.  South African guideline for the management of community-acquired pneumonia in adults.

Authors:  Tom H Boyles; Adrian Brink; Greg L Calligaro; Cheryl Cohen; Keertan Dheda; Gary Maartens; Guy A Richards; Richard van Zyl Smit; Clifford Smith; Sean Wasserman; Andrew C Whitelaw; Charles Feldman
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

Review 2.  The Use of Statins and Risk of Community-Acquired Pneumonia.

Authors:  Mohammed A Batais; Abdur Rahman Khan; Aref A Bin Abdulhak
Journal:  Curr Infect Dis Rep       Date:  2017-08       Impact factor: 3.725

3.  Mortality benefit of statin use in traumatic spinal cord injury: a retrospective analysis.

Authors:  M D Stillman; C E Aston; M H Rabadi
Journal:  Spinal Cord       Date:  2015-10-20       Impact factor: 2.772

Review 4.  Possible immunosuppressive effects of drug exposure and environmental and nutritional effects on infection and vaccination.

Authors:  H P Huemer
Journal:  Mediators Inflamm       Date:  2015-04-05       Impact factor: 4.711

Review 5.  Recent advances in our understanding of Streptococcus pneumoniae infection.

Authors:  Charles Feldman; Ronald Anderson
Journal:  F1000Prime Rep       Date:  2014-09-04

6.  Community-Acquired Pneumonia in HIV-Infected Individuals.

Authors:  James Brown; Marc Lipman
Journal:  Curr Infect Dis Rep       Date:  2014-03       Impact factor: 3.725

7.  Passive immune therapy and other immunomodulatory agents for the treatment of severe influenza: Systematic review and meta-analysis.

Authors:  Vanessa W Lim; Lorainne Tudor Car; Yee-Sin Leo; Mark I-Cheng Chen; Barnaby Young
Journal:  Influenza Other Respir Viruses       Date:  2019-11-16       Impact factor: 4.380

Review 8.  Key mechanisms governing resolution of lung inflammation.

Authors:  C T Robb; K H Regan; D A Dorward; A G Rossi
Journal:  Semin Immunopathol       Date:  2016-04-27       Impact factor: 9.623

9.  Occurrence of pneumonitis following radiotherapy of breast cancer - A prospective study.

Authors:  Danijela Vasiljevic; Christoph Arnold; David Neuman; Katharina Fink; Marina Popovscaia; Irma Kvitsaridze; Meinhard Nevinny-Stickel; Markus Glatzer; Peter Lukas; Thomas Seppi
Journal:  Strahlenther Onkol       Date:  2018-02-15       Impact factor: 3.621

Review 10.  Pharmaco-Immunomodulatory Therapy in COVID-19.

Authors:  John G Rizk; Kamyar Kalantar-Zadeh; Mandeep R Mehra; Carl J Lavie; Youssef Rizk; Donald N Forthal
Journal:  Drugs       Date:  2020-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.